Groundbreaking Technology
Our patented technology utilizes non-invasive Vestibular Resonance Therapy (nVRT) to impact the vestibular system.
First Vertigo Wearable
We are developing a noninvasive and easy-to-use wearable solution for chronic vertigo, which is suffered by over 11 million Americans.
Non-Invasive, Non-Pharmacological
The compact, headworn wearable device requires no surgery, advanced patient calibration, or complex fittings.
Designed To Be Safe
Through development and clinical studies, our device has been used on over 600 subjects, with zero reportable serious device-related adverse events.
Enroll Now!
At-home Vertigo Study
Enrollment is limited and there is no cost to you. The investigational device is a new wearable intended to manage the symptoms of vertigo.
- Age Range: 18-75
- Enrollment: Approx. 50 days
- Compensation: Up to $420
Working With
Working
With
Latest News
Otolith Labs Rounds Out Executive Team with Hiring of Chief Clinical Officer
Kevin Franck, PhD, MBA appointed as Otolith Labs’ Chief Clinical Officer.
Otolith Expands Leadership Team with CCO and New Board Member
Otolith appointed Dan Wagner as Chief Commercial Officer and Raphael Michel to Otolith’s Board of Directors.
Mark Cuban-Backed Otolith Labs Just Raised Another $20M
Technical.ly interviews Otolith’s CEO Sam Owen about the pressing need for a new treatment option for chronic vertigo.
Otolith Receives FDA Breakthrough Device Designation
Otolith Labs announces closing of $3.3 Million in seed funding, as well as receiving “Breakthrough Device” Designation from FDA.
200 Massachusetts Ave NW, Floor 7, Washington, DC 20001
© 2024 Otolith Labs, Inc.